Evidence map›Paper›PMID 40301032›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Lorlatinib Induced Non-cardiogenic Pulmonary Edema.

Suzuka Matsuoka, Hiromi Watanabe, Tomoyoshi Inoue, Yuki Takigawa, Kenichiro Kudo, Akiko Sato, Ken Sato, Keiichi Fujiwara, Takuo Shibayama

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Suzuka MatsuokaDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Hiromi WatanabeDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Tomoyoshi InoueDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Yuki TakigawaDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Kenichiro KudoDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Akiko SatoDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Ken SatoDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Keiichi FujiwaraDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Takuo ShibayamaDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 71-year-old woman was diagnosed with anaplastic lymphoma kinase-positive metastatic lung adenocarcinoma staged as cT1cN3M1c (8th edition). Treatment with lorlatinib (100 mg) was initiated on a daily basis. Three weeks after the first dose, the patient was hospitalized because of lorlatinib-induced noncardiogenic pulmonary edema. The patient's condition improved with diuretic therapy, and lorlatinib was rechallenged at a reduced dose. Follow-up computed tomography revealed a partial response. This is a rare case of non-cardiogenic pulmonary edema as an adverse effect of lorlatinib.

Indexed as

Lactams, MacrocyclicLung NeoplasmsPulmonary EdemaAdenocarcinomaAdenocarcinoma of LungAgedAminopyridinesFemaleHumansLactamsPyrazolesAminopyridinesLactamsLactams, MacrocycliclorlatinibPyrazolesALK-positive lung adenocarcinomalorlatinibnon-cardiogenic pulmonary edema

Identifiers

PMID40301032
PMCPMC12659957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.